FDA Approved: LAMICTAL ODT — Supplemental Application (GlaxoSmithKline LLC)

View source ↗

Summary

FDA approved a supplemental application for Lamictal ODT (lamotrigine) filed by GlaxoSmithKline, resulting in changes to the product labeling.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Bipolar Disorder
• Epilepsy

Drugs mentioned

• LAMICTAL ODT (lamotrigine)

Snippet

SUPPL AP for LAMICTAL ODT (LAMOTRIGINE)